NECLIFE vs WOCKPHARMA: Stock Comparison

NECTAR LIFESCIENCES vs WOCKHARDTUpdated 4 Sept 26, 4:08 PM ISTNSE & company filings

WOCKHARDT is the larger company by market capitalisation. NECTAR LIFESCIENCES shows a lower P/E and lower leverage, while WOCKHARDT shows a higher ROE, faster revenue growth and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

NECLIFE leads 5; WOCKPHARMA leads 5 of 12

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

NECLIFEWOCKPHARMA

Valuation lens

What price are you paying?

Market CapContext only
₹237 Cr
₹33,908 Cr
P/E RatioNECLIFE has the lower reading
0x
75.68x
P/B RatioNECLIFE has the lower reading
0.4x
6.27x
EPSWOCKPHARMA has the higher reading
₹-0.68
₹6.58
Book ValueContext only
₹29.97
₹325
Dividend YieldSame reading
0%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
WOCKPHARMA is the larger company
₹33,908 Cr vs ₹237 Cr
P/E Ratio
NECLIFE has a lower P/E
0x vs 75.68x
P/B Ratio
NECLIFE has a lower P/B
0.4x vs 6.27x
EPS
WOCKPHARMA has higher earnings per share
₹6.58 vs ₹-0.68
Revenue Growth (TTM YoY)
WOCKPHARMA has faster revenue growth
26% vs -3.41%
Qtr Sales Growth
NECLIFE has stronger quarterly sales growth
0% vs -39.61%
Qtr Profit Growth
NECLIFE has stronger quarterly profit growth
16.44% vs 0%
ROE
WOCKPHARMA has a higher ROE
10.28% vs -9.85%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricNECLIFEWOCKPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricNECLIFEWOCKPHARMA
Live Price₹12.19₹2,088.7
Day Change0.16%7.08%
Volume2.05 L35.58 L
52-Week High₹21.4₹2,422.3
52-Week Low₹9.3₹1,086.7
Distance from 52W High-43.04%-13.77%

Valuation

MetricNECLIFEWOCKPHARMA
Market Cap₹237 Cr₹33,908 Cr
P/E Ratio0x75.68x
P/B Ratio0.4x6.27x
EPS₹-0.68₹6.58
Book Value₹29.97₹325
Dividend Yield0%0%

Growth

MetricNECLIFEWOCKPHARMA
Revenue Growth (TTM YoY)-3.41%26%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth0%-39.61%
Qtr Profit Growth16.44%0%

Profitability & Leverage

MetricNECLIFEWOCKPHARMA
ROE-9.85%10.28%
ROCE-8.89%10.37%
Net Margin-11.28%3.3%
Operating Margin28.35%
Debt to Equity0x0.57x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricNECLIFEWOCKPHARMA
Promoter Holding51.84%49.08%
FII Holding0.5% 0.1 pp7.22% 0.13 pp
DII Holding3.74% 0.27 pp9.24% 1.72 pp
Public Holding43.89% 0.37 pp34.44% 1.61 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: NECTAR LIFESCIENCES and WOCKHARDT.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.